10-Q: Klotho Neurosciences Reports Increased Net Loss in Q3 2024 Following Business Combination

Klotho Neurosciences, Inc. reports a significant increase in net loss for the third quarter of 2024, primarily due to increased share-based compensation and expenses related to its recent business combination.

Summary

• Klotho Neurosciences, Inc. reported a net loss of $2,959,426 for the three months ended September 30, 2024, compared to a net loss of $144,111 for the same period in 2023.
• The company's operating expenses for the quarter were $2,870,932, a substantial increase from $123,737 in the prior year, driven by higher share-based compensation and professional fees.
• For the nine months ended September 30, 2024, the net loss totaled $4,083,109, compared to $580,983 in 2023.
• The company's cash balance stood at $50,895 as of September 30, 2024, with an accumulated deficit of approximately $8.5 million.
• Klotho Neurosciences is in a pre-revenue stage and is dependent on additional funding to continue operations.
• The company completed a business combination on June 21, 2024, which was treated as a reverse acquisition for accounting purposes.
• The company issued 4,050,617 shares of common stock to settle $4,010,022 in convertible promissory notes during the third quarter of 2024.
• The company is facing potential delisting from Nasdaq due to non-compliance with minimum market value and share price requirements.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including substantial losses, low cash reserves, and potential delisting from Nasdaq. While the company has completed a business combination and acquired licenses, the overall outlook is concerning due to the company's dependence on additional funding and weak internal controls.

Positives

• The company completed a business combination, which is a significant step in its development.
• The company has acquired several licenses and patents for potential future products.
• The company has secured $2,173,942 in financing activities during the nine months ended September 30, 2024.

Negatives

• The company has incurred significant operating losses and negative cash flows since inception.
• The company's cash balance is very low at $50,895 as of September 30, 2024.
• The company has a substantial accumulated deficit of approximately $8.5 million.
• The company is facing potential delisting from Nasdaq due to non-compliance with minimum market value and share price requirements.
• The company's disclosure controls and procedures were deemed ineffective due to inadequate accounting resources and lack of segregation of duties.

Risks

• The company is dependent on obtaining additional working capital funding to continue operations, and there is substantial doubt about its ability to continue as a going concern.
• The company is facing potential delisting from Nasdaq if it fails to regain compliance with listing rules by February 12, 2025 and April 14, 2025.
• The company's internal controls over financial reporting are weak, which could lead to misstatements in financial reports.
• The company is in a pre-revenue stage and has not generated any operating revenues to date.
• The company has incurred significant transaction costs related to the business combination.

Future Outlook

The company expects net cash used in operating activities to increase until its products are able to produce meaningful revenue. The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations.

Management Comments

• Management believes that the material weaknesses in internal controls are due to the small size of the accounting staff.
• Management believes that despite the material weaknesses, the financial statements for the quarter ended September 30, 2024, are fairly stated in all material respects, in accordance with GAAP.

Industry Context

The company is operating in the biotechnology and pharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on cancer, cardiovascular, and neurodegenerative disorders aligns with significant unmet medical needs and market opportunities. The company's reliance on licensing and acquisitions is a common strategy in the industry to access new technologies and products.

Comparison to Industry Standards

• The company's significant net losses and negative cash flows are not uncommon for early-stage biotechnology companies that are in the pre-revenue phase.
• The company's reliance on external funding is typical for companies in this sector, as they often require substantial capital to fund research, development, and clinical trials.
• The company's focus on licensing and acquisitions is a common strategy in the industry to access new technologies and products, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The company's challenges with Nasdaq listing compliance are not unique, as many small-cap biotech companies face similar issues due to market volatility and funding constraints.
• The company's internal control weaknesses are a concern, as robust controls are essential for maintaining investor confidence and ensuring accurate financial reporting, similar to the issues faced by other companies with rapid growth or complex transactions.

Management Changes

Corporate Governance

Related Party Transactions

• The company issued promissory notes to members of management totaling $151,000 as of September 30, 2024.
• The company's CEO is owed $0 as of September 30, 2024, but was owed $80,000 as of December 31, 2023.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and potential delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial challenges.
• Customers and suppliers may be impacted by the company's ability to continue operations and fulfill its obligations.
• Creditors face increased risk due to the company's low cash balance and high debt levels.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company must regain compliance with Nasdaq listing rules by February 12, 2025 and April 14, 2025 to avoid delisting.
• The company needs to strengthen its internal controls over financial reporting.
• The company needs to develop its licensed platforms and patents to generate revenue.

Key Dates

Keywords

Klotho Neurosciences, business combination, reverse acquisition, net loss, operating expenses, share-based compensation, Nasdaq delisting, convertible promissory notes, biologics, gene therapy, pharmaceuticals, insider trading